CT-assisted transbronchial brachytherapy for small peripheral lung cancer

Transbronchial brachytherapy for small peripheral lung cancer was developed with the use of the CT-guided bronchoscopy technique. Under CT guidance, an applicator carrying a dummy source was introduced into a lesion and stabilized. A radioactive source was then delivered through the applicator using a high dose rate remote afterloading system. For multiple radiation fractions, a marker was placed immediately under the pleura in a peripheral bronchus penetrating the lesion using the CT-guided barium marking technique. During brachytherapy, an applicator with a dummy source was inserted under fluoroscopic guidance up to the marker. A radioactive source was subsequently delivered. CT-assisted transbronchial brachytherapy allows radiation to be delivered from inside a lesion. This minimizes radiation damage to noncancerous tissue and offers distinct advantages over conventional radiation techniques.     

The optimization of dose delivery for intraoperative high-dose-rate radiation therapy using curved HAM applicators.

BACKGROUND AND PURPOSE: To determine the effect of the curvature of Harrison-Anderson-Mick applicators on the dose distribution in high-dose-rate intraoperative radiation therapy (HDR-IORT). MATERIAL AND METHODS: Treatment planning was performed with flat applicators using (192)Ir as the radioactive source, and dwell times were optimized using dose-point optimization techniques. These optimized dwell times were then used for the curved applicators, and the dose distributions that would actually be delivered to patients were determined. RESULTS: The dose directly below the central catheter was strongly dependent on the curvature of the applicator. Steep parabolic curves caused underdoses of as much as 19% at a point 1cm from the convex side of the applicator. The rate of dose reduction with increasing distance from the applicator surface was also a function of the curvature of the applicator. CONCLUSIONS: The curvature of the applicator profoundly affects dosimetry and can be exploited to optimize coverage of the target during HDR-IORT procedures. To ensure accurate dose delivery, these dose perturbations must be accounted for in the planning process. We recommend maintaining a dosimetry atlas of various applicator sizes and curvatures in addition to one for flat applicators.     

Development of an inductive,non-invasive RF applicator for studying hyperthermia in a rat brain tumour model

A non-invasive inductive RF applicator has been designed specially for local heating of 6 mm diameter tumours growing in the brains of F344 rats (144–148 MHz). It is shown that an inductive applicator is the choice for this particular case. The power deposition pattern is analysed by modelling the applicator with a three-dimensional array of magnetic dipoles. The total hyperthermia system is briefly described and results of phantom and in vivo experimental measurements are presented. These confirm the theoretical analysis.     

Design and thermometry of an intracavitary microwave applicator suitable for treatment of some vaginal and rectal cancers

The construction of a modified coaxial cable as an intracavitary microwave applicator suitable for use in some vaginal and rectal cancers is presented. Thermometry was performed for microwave frequencies of 300, 400, 650, and 915 MHz. Temperature profiles in tissue phantoms were obtained with non-perturbing temperature probes and thermography, and the data were compared with those obtained in dogs. The temperature profiles were dependent on the frequency of the microwaves and the insertion depth of the applicator. In addition, an acrylic cylindrical spacer external to the applicator also altered the heating pattern. Therefore, with proper combinations of frequency, insertion depth and spacer, the applicator can be used for heating tumors in some clinical situations.     

The position of the opposite flat applicator changes the SAR and thermal distributions of the RF capacitive intracavitary hyperthermia

The variations of the specific absorption rate (SAR) and thermal distribution in the JSHO QA phantoms were investigated by radiofrequency (RF) capacitive intracavitary hyperthermia (ICHT) applicator (AP-T01, Omron Electric Co., Kyoto, Japan) with the changing position of the opposite flat applicator (15-cm in diameter). The thermal distribution was observed with the thermographic camera and the normalized SAR distribution was calculated with the thermal data that were measured with the thermocouple thermometers. The SAR and thermal distributions of AP-T01 significantly varied with the position of the opposite flat applicator. The slope of the normalized SAR became gradual towards the side of the flat applicator. During the operating of a high flow rate (1500ml/min) cooling system, the region between AP-T01 and the flat applicator was widely and rather homogeneously heated, except the hot spot around the end of AP-T01. This hot spot may be due to the imbalance of cooling of AP-T01 and the warming-up of the electrode. These results suggest that the RF capacitive ICHT using AP-T01 may be clinically effective on the deep-seated tumours in the direction of either the end wall, such as cervical cancers, or the upper wall, such as prostatic cancers and the mediastinal metastatic lymph nodes, if an improvement of the cooling system is achieved.     

The novel technique of delivering targeted intraoperative radiotherapy (Targit) for early breast cancer.

AIM: We believe that conservative treatment of early breast cancer may not require radiotherapy that encompasses the whole breast in all patients. We have developed a novel therapeutic approach that allows targeted intraoperative radiotherapy (Targit) to be safely and accurately delivered in a standard operating theatre. We are currently recruiting for a randomized trial testing whether Targit can replace the whole 6 weeks of post-operative radiotherapy after breast conserving surgery. METHODS: This paper describes the operative technique. It employs a miniature electron-beam-driven X-ray source called INTRABEAM (PeC) that emits soft X-rays (50 kV) from within the breast. The X-rays are emitted from the tip of a 10 cm x 3.2 mm diameter probe, that is enclosed in a spherical applicator (available in 2.5-5 cm diameter sizes), which in turn is inserted in the tumour bed and intraoperative radiotherapy is delivered in about 25 min. The prescribed dose is 5 and 20 Gy at 1 cm and 0.2 cm respectively, from the tumour bed. RESULTS: The biologically effective dose is 7-53 Gy for alpha/beta=10 and 20-120 Gy for alpha/beta=1.5. The quick attenuation of the radiation reduces the damage to normal tissues and allows radiotherapy to be delivered in a standard operating theatre. Tungsten impregnated rubber sheets, cut to size, are placed on the chest wall to protect the heart/lungs and over the wound to stop stray radiation. The skin dose is monitored with thermoluminescent detectors (TLDs). After wide local excision of the tumour and good haemostasis, a spherical applicator is inserted in the tumour bed and the target breast tissues are wrapped around it with a purse-string suture. Thus, true conformation of the target around the applicator source is achieved in real time. CONCLUSION: As a tumour bed boost, this technique has the potential to reduce local recurrence by avoiding geographical misses and achieving excellent dosimetry. In patients with low risk of local recurrence, it has the potential to replace the full 6 weeks of post-operative radiotherapy with considerable implications to patients and hospitals.     

The position of the opposite flat applicator changes the SAR and thermal distributions of the RF capacitive intracavitary hyperthermia.

The variations of the specific absorption rate (SAR) and thermal distribution in the JSHO QA phantoms were investigated by radiofrequency (RF) capacitive intracavitary hyperthermia (ICHT) applicator (AP-T01, Omron Electric Co., Kyoto, Japan) with the changing position of the opposite flat applicator (15-cm in diameter). The thermal distribution was observed with the thermographic camera and the normalized SAR distribution was calculated with the thermal data that were measured with the thermocouple thermometers. The SAR and thermal distributions of AP-T01 significantly varied with the position of the opposite flat applicator. The slope of the normalized SAR became gradual towards the side of the flat applicator. During the operating of a high flow rate (1500 ml/min) cooling system, the region between AP-T01 and the flat applicator was widely and rather homogeneously heated, except the hot spot around the end of AP-T01. This hot spot may be due to the imbalance of cooling of AP-T01 and the warming-up of the electrode. These results suggest that the RF capacitive ICHT using AP-T01 may be clinically effective on the deep-seated tumours in the direction of either the end wall, such as cervical cancers, or the upper wall, such as prostatic cancers and the mediastinal metastatic lymph nodes, if an improvement of the cooling system is achieved.     

Postoperative beta radiation treatment of pterygium

A retrospective analysis of 69 patients with diagnosis of pterygium who underwent surgical removal of the pterygium and postoperative beta radiation from a Strontium-90 (Sr-90) applicator from January, 1973, to December, 1977, is presented. The radiation treatment was delivered 2–48 hrs postoperatively after surgical removal of the pterygium. Those few patients who received beta radiation after more than 56 hours postoperatively were not included in the analysis because of the small number of patients in this group. Thirty-two patients had bilateral pterygium; 18 patients from this group received radiation treatment to one eye only. A total of 83 eyes have been irradiated in the whole group. A total dose of 1800–2200 rad equivalent of beta radiation was delivered to the edge of the cornea and surgical bed of the pterygium in the conjunctiva. Measurement by phantom showed that the dose to the anterior surface of the lens will be approximately 70–90 rad, and the dose to the retina will be 4–8 rad during a single dose of 1800–2200 rad equivalent of beta radiation to the conjunctiva and pterygium bed. Thirty-nine percent of the nonirradiated eyes after removal of the pterygium developed recurrence, whereas only 5% of the irradiated eyes developed recurrence. Nineteen percent of the irradiated eyes developed cataract as well as 10% of the nonirradiated eyes. These include all detectable cataracts, some of which did not require lens removal. Local cortisone therapy reduced the progression of the recurrent disease for a few months and partial regression was seen in four eyes, but there was no complete regression of any recurrent pterygium with topical cortisone therapy. This retrospective study showed that postoperative 1800–2200 rad beta radiation from a Strontium-90 applicator, if delivered 2–48 hours postoperatively, is effective in reducing the recurrence rate. It has acceptable range of complication if it is administered by an experienced radiation therapist and calculation and calibration are done precisely. The immediate and late side effects and complications of beta radiation from a Strontium applicator are discussed, and the dose delivered to the cornea, sclera, lens, and retina with this radiation treatment are shown.     

Novel prostate brachytherapy technique: Improved dosimetric and clinical outcome

PURPOSE: Erectile dysfunction following prostate brachytherapy is reported to be related to dose received by the penile bulb. To minimise this, whilst preserving prostate dosimetry, we have developed a technique for I-125 seed brachytherapy using both stranded seeds and loose seeds delivered with a Mick applicator, and implanted via the sagittal plane on trans-rectal ultrasound. MATERIALS AND METHODS: Post-implant dosimetry and potency rates were compared in 120 potent patients. In Group 1, 60 patients were treated using a conventional technique of seeds implanted in a modified-uniform distribution. From January 2005, a novel technique was developed using stranded seeds peripherally and centrally distributed loose seeds implanted via a Mick applicator (Group 2). The latter technique allows greater flexibility when implanting the seeds at the apex. Each patient was prescribed a minimum peripheral dose of 145 Gy. No patients received external beam radiotherapy or hormone treatment. There was no significant difference in age or pre-implant potency score (mean IIEF-5 score 22.4 vs. 22.6, p=0.074) between the two groups. RESULTS: The new technique delivers lower penile bulb doses (D(25) as %mPD - Group 1: 61.2+/-35.7, Group 2: 29.7+/-16.0, p<0.0001; D(50) as %mPD - Group 1: 45.8+/-26.9, Group 2: 21.4+/-11.7, p<0.0001) whilst improving prostate dosimetry (D(90) - Group 1: 147 Gy+/-21.1, Group 2: 155 Gy+/-16.7, p=0.03). At 2 years, the potency rate was also improved: Group 1: 61.7%; Group 2: 83.3% (p=0.008). CONCLUSIONS: In this study, the novel brachytherapy technique using both peripheral stranded seeds and central loose seeds delivered via a Mick applicator results in a lower penile bulb dose whilst improving prostate dosimetry, and may achieve higher potency rates.     

Simulation of different applicator positions for treatment of a presacral tumour.

INTRODUCTION: Proximally located presacral recurrences of rectal carcinomas are known to be difficult to heat due to the complex anatomy of the pelvis, which reflect, shield and diffract the power. This study is to clarify whether a change of position of the Sigma-Eye applicator in this region can improve the heating. MATERIAL AND METHODS: Finite element (FE) planning calculations were made for a phantom model with a proximal presacral tumour using a fixed 100 MHz radiofrequency radiation. Shifts of the applicator were simulated in 1 cm steps in x-(lateral), y-(posterior) and z-(longitudinal) direction. Computations also considered the network effects of the Sigma-Eye applicator. Optimisation of the phases and amplitudes for all positions were performed after solving the bioheat-transfer-equation. The parameters T90, T50, sensitivity, hot spot volume and total deposited power have been sampled for every applicator position with optimised plans and a standard plan. RESULTS: The ability to heat a presacral tumour clearly depends on the applicator position, for standard antenna adjustment and also for optimised steering of the Sigma-Eye applicator. The gamma-direction (anterior-posterior) is very sensitive. Using optimised steering for each position, in z-direction (longitudinal), we found an unexpected additional optimum at 8 cm cranial from the middle position of the phantom. The x-direction (lateral) is in a clinical setting less important and shows only smaller changes of T90 with an expected optimum in the central position. A positioning of the applicator in the axial and anterior position of the mid-pubic symphysis should be avoided for treatment of the presacral region, regardless of the used adjustment. Use of amplitude and phase optimisation yields better T90 values than plans optimised only by phases, but they are much more sensitive for small variations of phases and amplitudes during a treatment, and the total power of the Sigma-Eye applicator can be restricted by the treatment software. CONCLUSIONS: Complex geometry of the human pelvis seems to be the reason for the difficulties to warm up the proximal presacral region. The assumption that every position can be balanced by a proper phase adaption, is true only in a small range. A centring of the applicator on the mid-pubic symphysis to heat this region should be avoided. From the practical point of view improved warming should be performed by optimisation of phases only.     

Radiation dosimetry of a conformal heat-brachytherapy applicator

The purpose of this paper is to report the radiation dosimetric characteristics of a new combination applicator for delivering heat and radiation simultaneously to large area superficial disease <1.5 cm deep. The applicator combines an array of brachytherapy catheters (for radiation delivery) with a conformal printed circuit board microwave antenna array (for heat generation), and a body-conforming 5-10 mm thick temperature-controlled water bolus. The rationale for applying both modalities simultaneously includes the potential for significantly higher response rate due to enhanced synergism of modalities, and lower peak toxicity due to temporal extension of heat and radiation induced toxicities. Treatment plans and radiation dosimetry are calculated with IPSA (an optimization tool developed at UCSF) for 15 x 15 cm(2) and 35 x 24 cm(2) applicators, lesion thicknesses of 5 to 15 mm, flat and curved surfaces, and catheter separation of 5 and 10 mm. The effect on skin dose of bolus thickness and presence of thin copper antenna structures between radiation source and tissue are also evaluated. Results demonstrate the ability of the applicator to provide conformal radiation dose coverage for up to 15 mm deep target volumes under the applicator. For clinically acceptable plans, tumor coverage is > 98%, homogeneity index > 0.95 and the percentage of normal tissue irradiated is < 20%. The dose gradient at the skin surface varies from 3 to 5 cGy/mm depending on bolus thickness and lesion depth. Attenuation of the photon beam by the printed circuit antenna array is of the order 0.25% and secondary electron emissions are absorbed completely within 5 mm of water bolus and plastic layers. Both phenomena can then be neglected in dose calculations allowing commercial software to be used for treatment planning. This novel applicator should prove useful for the treatment of diffuse chestwall disease located over contoured anatomy that may be difficult to treat with single field external beam therapy. By delivering heat and radiation simultaneously, increased synergism is expected with a TER in the range of 2-5. Lowering radiation dose by an equivalent factor may produce lower radiation toxicity with similar efficacy, while preserving the option of subsequent retreatment(s) with thermoradiotherapy in order to further extend patient survival.     

Results of a non-controlled trial of hyperthermia combined with radiation for superficial tumours

Fifty-four patients with 65 superficial malignant lesions were treated by local hyperthermia combined with radiation therapy at the National Cancer Center Hospital, Tokyo. Hyperthermia was delivered with an Aloka Model HMS-020 (2450 MHz) or with a horn-type applicator of BSD-1000 (80–90 MHz). Relatively small tumours, those less than 4 cm in thickness, were treated by using 2450 MHz while 80–90 MHz delivered through the horn-type applicator was used for tumours exceeding 5 cm in thickness. The radiation dose was 4 Gy twice a week or 2 Gy five times a week, the total dose being 40–60 Gy. A total of six to 10 hyperthermia treatments ranging from 40 to 60 min each, with the tumour heated to more than 42.5°C, were given twice a week within 1 h following radiation therapy. Complete response was achieved in 16 of the 30 patients (55 per cent) treated with the 2450 MHz microwave, and partial response in seven others (23 per cent). Tumours treated with the BSD-1000 achieved complete response in 10 out of 33 patients (30 per cent) and partial response in nine others (27 per cent). In five out of nine patients classified as partial responders, however, complete disappearance of tumour cells was noted by post-treatment histological examination. Complete plus partial response rates were thus essentially the same with the Aloka HMS-020 and the BSD-1000, though the rate of complete response was apparently higher with the Aloka unit, probably because it was used on smaller tumours.     

Results of a non-controlled trial of hyperthermia combined with radiation for superficial tumours

Fifty-four patients with 65 superficial malignant lesions were treated by local hyperthermia combined with radiation therapy at the National Cancer Center Hospital, Tokyo. Hyperthermia was delivered with an Aloka Model HMS-020 (2450 MHz) or with a horn-type applicator of BSD-1000 (80-90 MHz). Relatively small tumours, those less than 4 cm in thickness, were treated by using 2450 MHz while 80-90 MHz delivered through the horn-type applicator was used for tumours exceeding 5 cm in thickness. The radiation dose was 4 Gy twice a week or 2 Gy five times a week, the total dose being 40-60 Gy. A total of six to 10 hyperthermia treatments ranging from 40 to 60 min each, with the tumour heated to more than 42.5 degrees C, were given twice a week within 1 h following radiation therapy. Complete response was achieved in 16 of the 30 patients (55 per cent) treated with the 2450 MHz microwave, and partial response in seven others (23 per cent). Tumours treated with the BSD-1000 achieved complete response in 10 out of 33 patients (30 per cent) and partial response in nine others (27 per cent). In five out of nine patients classified as partial responders, however, complete disappearance of tumour cells was noted by post-treatment histological examination. Complete plus partial response rates were thus essentially the same with the Aloka HMS-020 and the BSD-1000, though the rate of complete response was apparently higher with the Aloka unit, probably because it was used on smaller tumours.     

红外热像图对良恶性乳房肿块鉴别诊断的价值

对２６０例单侧性乳房肿块的女性患者作红外热像图检查，按作者提出孤五项阳性指标进行判读，其结果与临床诊断和病理检查相对照。恶性病变１１８例，良性病变１４２例，用红外热像图作良，恶性病变的鉴别诊断，其敏感性为９３．２％，特异性为７４．０％，Ｙｏｕｄｅｎ指数为０．６７，与病变诊断的符合率为８２．７％，大于临床诊断和闰理诊断的符合率。     

PET-guided three-dimensional treatment planning of intracavitary gynecologic implants

PURPOSE: Positron emission tomography (PET) provides physiologic information that is not available from computed tomography (CT) or magnetic resonance studies. PET images may allow more accurate delineation of three-dimensional treatment planning target volumes of brachytherapy gynecologic (GYN) implants. This study evaluates the feasibility of using PET as the sole source of target, normal structure, and applicator delineation for intracavitary GYN implant treatment planning. MATERIALS AND METHODS: Standard Fletcher-Suit brachytherapy tandem and colpostat applicators were used for radiation delivery. After insertion of the applicator in the operating room, the patient was taken to a PET scanner, where 555 MBq (15 mCi) 18F-fluorodeoxyglucose (18F-FDG) was administered intravenously. Forty-five minutes later, three localization tubes containing 18F-FDG were inserted into the source afterloading compartments of the tandem and colpostat. A whole-pelvis scan was performed, and the images were transferred to a commercial brachytherapy three-dimensional treatment planning system. A Foley catheter was inserted into the urinary bladder while the patient was in the operating room. The regions of radioactivity in the three applicator tube image were contoured for reconstruction of the applicator, along with the bladder, rectum, and 18F-FDG-defined target volumes. A treatment plan was generated that included dose-volume histograms and three-dimensional dose distribution displays, allowing the physician an opportunity to determine if adequate target coverage and normal-tissue sparing had been obtained. For a more conservative approach, three-dimensional dose distributions and dose-volume histograms delivered with conventional source arrangements and loading could be observed. The accuracy of applicator localization from the PET images was verified using a water phantom containing two aluminum CT-compatible tandems. The PET-defined and CT scan applicator reconstructions were compared. RESULTS: Feasibility of using PET images for treatment planning of brachytherapy intracavitary GYN implants has been demonstrated. A phantom study demonstrated applicator reconstruction accuracy in the axial direction to be better than 2 mm. Reconstruction accuracy in the longitudinal direction (principally craniocaudal) was similar to the PET scanner's voxel size of 4.3 mm. CONCLUSIONS: Brachytherapy intracavitary GYN implant design has traditionally been based on patient tumor staging, palpation, and clinical experience. PET images have the potential to provide better spatial information about the relationship of tumor and normal structures to the applicator. This information can be used to optimize the delivery of radiation therapy treatments. Thus far, six patients have been scanned using this process.     

Peripheral neuropathy and myonecrosis following hyperthermia and radiation therapy for recurrent prostatic cancer: correlation of damage with predicted SAR pattern.

During the past 10 years, numerous phase I-II studies were conducted and provided clinical experience with combined radiation therapy and hyperthermia treatments. Among the rare complications reported in these combined radiation therapy-hyperthermia trials were myonecrosis and peripheral neuropathy which were felt, mainly on a clinical basis, to be caused by local heat damage. Recently, such complications were noted in two patients with recurrent prostatic cancer treated in our department with radiation therapy combined with deep regional hyperthermia delivered by the Sigma-60 applicator of the BSD 2000 hyperthermia system (Salt Lake City, UT, USA). Analysis of the results of three-dimensional modelling of the SAR (specific absorption rate, W/kg) pattern in these patients indicated high SAR at the sites of the complications. Pretreatment three-dimensional modelling or other methods of predicting potential areas of high power deposition may have a role for future hyperthermia treatment planning aiding in the prevention of possible local heat damage and providing improved delivery of heat to the target volume.     

Development of an inductive, non-invasive RF applicator for studying hyperthermia in a rat brain tumour model

A non-invasive inductive RF applicator has been designed specially for local heating of 6 mm diameter tumours growing in the brains of F344 rats (144-148 MHz). It is shown that an inductive applicator is the choice for this particular case. The power deposition pattern is analysed by modelling the applicator with a three-dimensional array of magnetic dipoles. The total hyperthermia system is briefly described and results of phantom and in vivo experimental measurements are presented. These confirm the theoretical analysis.     

Electrical-thermal performance of a cooled RF applicator for hepatic ablation with additional distant infusion of hypertonic saline: In vivo study and preliminary computer modeling

Purpose: The Cool-tip electrode is one of the most widely employed applicators in radiofrequency (RF) hepatic ablation. Previous research demonstrated that it is possible to enlarge coagulation volume when the single cooled electrode is associated with distant infusion of saline (hybrid applicator). The aim of this study was to compare the electrical-thermal behaviour of the Cool-tip electrode with that of the hybrid applicator.

Materials and methods: Forty-two RF ablations were performed on a total of 10 pigs: 22 with the Cool-tip electrode and 20 with the hybrid applicator (low infused saline volumetric flow rate of 6?mL/h at 2?mm distance). We compared both electrical performance (delivered power and number of roll-offs, i.e. sudden rises in impedance that interrupt the power delivery) and coagulation zone characteristics. In addition, we built a one-dimensional model to provide a basic physical explanation of the difference in performance between the different applicators.

Results: The experimental results showed that the number of roll-offs with the Cool-tip electrode was higher (24.3?±?3.1 versus 6.7?±?7.0). The hybrid applicator created larger coagulation volumes (19.7?±?9.5 cm³ versus 9.5?±?5.8 cm³) with larger transverse diameters (2.5?±?0.6 versus 1.9?±?0.5?cm). The one-dimensional model confirmed the delay in the incidence of the first roll-off, but not the heterogeneity of the hybrid applicator's electrical performance in the experiments.

Conclusions: The hybrid applicator produces fewer roll-off episodes than the Cool-tip electrode and creates larger coagulation volumes with larger transverse diameters.     

Postoperative vaginal irradiation by a high dose-rate afterloading technique in endometrial carcinoma stage I

A high dose-rate (cobalt-60) afterloading technique was used for postoperative vaginal irradiation in a series of 404 women with endometrial carcinoma stage I. The total recurrence rate was 3.7% with 0.7% vaginal lesions. The crude 5-year survival rate for the complete series was 91.8% compared to 13.3% for those with recurrences. Depth of myometrial infiltration (greater than 1/3 of the uterine wall) and nuclear grade were the most important prognostic factors. Clinically significant late radiation reactions (bladder and/or rectum) were recorded in 6.9%. The absorbed dose per fraction and the size of the treatment volume were significantly related to the occurrence of both early and late radiation reactions. Vaginal shortening was closely related to the dose per fraction, length of the reference isodose and the applicator diameter. The shape of the vaginal applicator versus the isodose contours and the importance of the source train geometry and relative activity for absorbed dose inhomogeneities within the treatment volume are discussed. Cumulative radiation effect (CRE) and linear-quadratic (LQ) calculations have been performed and related to tissue reactions within the target volume and in the risk organs. An alpha-beta quotient of 8.8 Gy for vaginal shrinkage effect and 2.0 Gy for late rectal complications are suggested on the basis of calculations using a maximum likelihood method for quantal radiation data.